Patient Selection for Modern T2D Agents

Slides:



Advertisements
Similar presentations
Journal Club 埼玉医科大学 総合医療センター 内分泌・糖尿病内科 Department of Endocrinology and Diabetes, Saitama Medical Center, Saitama Medical University Sellami Mnif Houda.
Advertisements

Guidelines.diabetes.ca | BANTING ( ) | diabetes.ca Copyright © 2013 Canadian Diabetes Association CHOICE OF AGENT AFTER INITIAL METFORMIN.
Case-Based Examination of Treatment Options in Type 2 Diabetes Management.
Taieb V, et al. Value Health Nov;18(7):A598.
Antihyperglycemic Agents and Renal Function
CV Risk Management in Diabetes: A Mandate for GLP-1 Receptor Agonists?
SGLT2 Inhibitors: What Do the Data Mean for My Patients?
Updates on Emerging GLP-1 Receptor Agonists
Updates on CVOT Data and Clinical Comparisons That Matter
SGLT2 Inhibitors and Their Clinical Impact:
Global Projections for Diabetes:
Expert Panelists. Emerging CV Outcomes Trial Results: What Do They Mean for T2D Management?
Patient Case Discussions in T2D: What Intensification Plan Is Best?
Updates on Outcomes for Novel T2D Therapies
Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.
SGLT2 Inhibitors in Phase 3 Trials
Clinical Advances in Type 2 Diabetes and Cardiovascular Risk
Updates Abound.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.
Goals. Achieving HbA1c Goals: Applying Guidelines to Intensify Therapy in Patients With Diabetes.
How Effective Is Fixed-Dose Combination Therapy in T2D and Where Does It Fit?
Clinical Application of New CV Outcomes Data
GLP-1 Receptor Agonists: How Early Is Appropriate?
T2DM and CV Outcomes Trials: A Deep Dive!
A Deep Dive Into CVOTs.
Expert Appraisal of CV Outcome Trial Results in T2DM for the Diabetologist.
ADA/EASD Position Statement: Approach to Hyperglycemia Management
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Diabetes and CV Risk Reduction: Cardiologists’ Perspectives on the Latest Outcomes Data.
SGLT2 inhibitors, Now Part of the Cardiology Toolkit for Comprehensive CV Risk Management.
Case Study Role of DPP-4 Inhibitors
2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Early and Intensive T2D Management:
Breaking Down the CVOTs
Antihyperglycemic therapy in type 2 diabetes: general recommendations
Novel Approaches in T1D Management
Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.
New Horizons in Adjunctive Type 1 Diabetes Management With SGLT Inhibitors.
T2DM, CV Safety, and Efficacy: DPP-4 Inhibitors in focus
LEADER One Year On.
Use of Combination of Saxagliptin/ Dapagliflozin in Patients With Poorly Controlled Diabetes on Metformin.
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
Learning Objectives Metabolic Abnormalities Associated With T2D.
Novel Approaches to T1D Management
Antihyperglycemic Therapy
Antihyperglycemic therapy in type 2 diabetes: general recommendations.
CV Outcomes and Adherence With GLP-1 RAs
T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight
CV Risk Reduction with Diabetes Drugs -- Should Cardiologists or Diabetologists Take the Lead?
The Role of the Kidney in Glucose Control
Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.
Oral Combination Therapy for T2D
Updates From ACC.
Add-On Therapy to Insulin in T1DM Management
Patients With T2D Presenting With Glycosuria: Examining the SGLT2 MOA
Improving Overall Health
2015 EASD In Review: CV Risk management in t2dm
Emerging Combination Injectable Therapy A New Era in Diabetes Care
Type 1 Diabetes: Expanding Options for Adjunctive Oral Therapy With SGLT Inhibitors.
Should SGLT2 Inhibitors Be the Primary Agents for CV Risk Reduction in T2DM?
Glucose-lowering medication in type 2 diabetes: overall approach.
What's New in Oral Combination Therapy for Type 2 Diabetes?
Emerging Advances in Reducing Renal Complications of T2D
BRIDGING CVD AND T2DM: LESSONS LEARNED FROM OUTCOME TRIALS
Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.
Renal licences of commonly used anti-diabetes drugs
Antihyperglycemic therapy in adults with type 2 diabetes
The Expanding Role of SGLT Inhibitors Across the Diabetes Spectrum
Presentation transcript:

Patient Selection for Modern T2D Agents

Program Goals

Patient-Centered Care

Modern Antihyperglycemic Agents

Case Study Role of DPP-4 Inhibitors

Case Discussion

Case Study Role of Fixed-dose Combination SGLT2/DPP-4 Inhibitor

Case Discussion

HbA1c Efficacy of Combination Empagliflozin and Linagliptin and Metformin

HbA1c Efficacy of Combination Dapagliflozin and Saxagliptin and Metformin

Combination SGLT2/DPP-4 Inhibitor in Treatment-Naïve Patients

CV Outcome Trials DPP-4 Inhibitors

CV Outcome Trials SGLT2 Inhibitors

Safety SGLT2 Inhibitors

Case Study Role of GLP-1 Agonists

Case Discussion

GLP-1 Receptor Agonists

Closing Comments

Abbreviations

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.